Seeking a Higher Standard for Degenerative Mitral Valve Repair: Begin with Etiology  by Adams, David H. & Anyanwu, Ani C.
Vol. 136, No. 3, September 2008
Seeking a Higher Standard for Degenerative Mitral Valve
Repair: Begin with Etiology
David H. Adams, MD, and Ani C. Anyanwu, MD
ED
IT
O
RI
A
LFrom the Department of Cardiothoracic
Surgery, Mount Sinai Medical Center, New
York, NY.
Received for publication Oct 8, 2007;
accepted for publication Oct 19, 2007.
Address for reprints: David H. Adams,
MD, Professor and Chairman, Department
of Cardiothoracic Surgery, Mount Sinai
Medical Center, 1190 Fifth Avenue, New
York, NY 10029, Telephone 212 659
6820, Fax 212 659 6818 (E-mail: david.
adams@mountsinai.org).
J Thorac Cardiovasc Surg 2008;136:551-6
0022-5223/$34.00
Copyright  2008 by The American Asso-
ciation for Thoracic Surgery
doi:10.1016/j.jtcvs.2007.10.060D
espite the widely held consensus that valve repair is the preferred surgical
treatment for patients suffering from degenerative mitral valve disease,
valve replacement for this condition remains all too prevalent. In the past
few years interest in mitral valve repair has expanded among cardiologists and sur-
geons, with the recognition that asymptomatic patients with severe mitral regurgita-
tion may be candidates for surgery provided they are likely to undergo valve repair
and obtain a durable result. We address both issues in the context of a recent article
published in the Journal, which explored the results of mitral valve repair in degen-
erative disease according to etiologic classification – Barlow’s disease or fibroelas-
tic deficiency.1 Most reports in the mitral valve repair literature define patient
subsets on the basis of leaflet dysfunction (posterior, anterior or bileaflet prolapse)
and repair techniques (chordal shortening or artificial chordoplasty; annuloplasty
ring or no annuloplasty ring, etc.), without clarification of the etiology of degener-
ative disease. Furthermore, these studies traditionally used patient survival and free-
dom from re-operation as the principal indicators of a durable result.2-4 Recently,
however, it has been appreciated that a proportion of patients free from reoperation
after mitral valve repair have significant recurrent mitral regurgitation5,6 implying
that freedom from reoperation is not a robust measure of durability of mitral valve
repair.
In their recent article, Flameng and co-workers1 introduced a fresh dimension into
mitral valve repair outcomes research, by attempting to define the long-term outcome
of mitral valve repair, including the freedom from recurrent mitral regurgitation, on
the basis of etiology of degenerative mitral valve disease. Their data suggest, perhaps
surprisingly, that, provided the surgical techniques were optimal, patients have a sim-
ilar rate of recurrent regurgitation after mitral valve repair regardless of whether the
original disease was Barlow’s or fibroelastic deficiency. There are several limitations
in their analysis which deserve emphasis and suggest the need for further study, in-
cluding retrospective classification of etiology and non-standardized and evolving
surgical techniques – both of which limit the robustness of outcomes data.7 Nonethe-
less, this emphasis on etiologic classification in outcomes analysis of degenerative
mitral valve repair is significant. We believe accurate etiologic classification is crucial
to outcomes research,7 and indeed to achieving a higher standard of clinical care,8 as it
does not seem logical that degenerative valves with very diverse characteristics
(Figure 1a, 1c) are considered the same.
What are the Differences in Degenerative Etiology?
We previously highlighted the importance of etiologic distinction in the field of de-
generative mitral valve repair.8 The surgical classification of degenerative mitral
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LFigure 1. Etiologic comparison of de-
generative mitral valve disease: Fibroe-
lastic deficiency resulting in chordal
rupture with single segment prolapse
[P1] (a). This valve was repaired with
a limited triangular resection and ring
annuloplasty (b). In contrast, Barlow's
disease (c) is characterized by multi-
segment prolapse and marked excess
tissue; repair technique included exten-
sive resection, annular plication, slid-
ing plasty, commisuroplasty and large
ring annuloplasty (d).valve disease is based predominantly on the pioneering
work of Carpentier and colleagues who defined the key dif-
ferentiating factors of these conditions in the 1970s. Bar-
low’s disease is often evident by early adulthood, and
most patients have been aware of a murmur or valve disease
for several years. They usually present with indications for
surgery in their fifth or sixth decade of life. Barlow’s dis-
ease is characterized by myxomatous degeneration affecting
the entire valve, resulting in excess leaflet tissue, leaflet bil-
lowing and multi-segmental prolapse and/or distension
(Figure 1c). Echocardiography usually shows a large valve
size with excess multi-segmental tissue and billowing of the
body of the leaflet(s). Late systolic prolapse in the setting of
chordal elongation may be observed or, conversely, early
systolic prolapse in the setting of ruptured chordae. Calcifi-
cation, leaflet restriction due to chordal fibrosis, and
posterior leaflet hinge displacement away from the atrio-
ventricular junction may be evident. In contrast fibroelastic
deficiency is a disease typically of older individuals over
the age of 60 years with a relatively short history of mitral
valve disease. Fibroelastic deficiency is essentially a chordal
disease in which presumed connective tissue deficiency pre-
disposes to chordal rupture, typically resulting in single seg-
ment prolapse (Figure 1a). In contrast to Barlow’s disease,
the leaflets are generally thin and without excess tissue ex-
cept in the prolapsing segment which may be distended
with myxomatous changes.9 Usually, the diagnosis can be
made on pre-operative echocardiography which suggests552 The Journal of Thoracic and Cardiovascular Surgery c Sepa normal sized valve with thin leaflets and minimal excess
tissue and isolated chordal rupture.
Carpentier’s group was the first to note that while these
two etiologic differentiations of degenerative disease can be
made in a majority of patients, a clear distinction between
Barlow’s disease and fibroelastic deficiency is not possible
in up to 20% of patients, even when surgical and histolog-
ical findings are taken into consideration.9 Etiologies un-
classifiable into either group include systemic connective
tissue disorders, formes frustes of Barlow’s disease, senile
degeneration, dystrophic calcification and idiopathic degen-
eration.9 Indeed Flameng et al noted in a prior article that ‘‘a
clear distinction remains difficult’’ between Barlow’s dis-
ease and fibroelastic deficiency,6 so it is somewhat surpris-
ing that they were able to classify all cases as Barlow’s
disease or fibroelastic deficiency in the current series.1 We
find patients with an intermediate valve size (32 to 34
mm) and a very distended P2 segment notoriously difficult
to classify. By forcing all patients into either Barlow’s dis-
ease or fibroelastic deficiency, Flameng et al1 likely mis-
classified a significant proportion of their patients. In our
recent Barlow’s series,10 we chose to restrict our definition
of Barlow’s disease to patients receiving a 36 mm or greater
ring, in order to define a pure Barlow’s subgroup with min-
imal potential of contamination bias from misclassified
fibroelastic deficiency cases. In the recent report by Fla-
meng and co-authors,1 40% of patients classified as having
Barlow’s disease received a ring size of 32 mm or less; suchtember 2008
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and it is likely that this group included several patients with
fibroelastic deficiency who were wrongly classified as
Barlow’s disease. This potential misclassification must be
taken into context when considering the implications of
their study.
What are the Surgical Implications of Degenerative
Etiology?
The etiology of degenerative mitral valve disease has several
important surgical implications which deserve emphasis. De-
generative etiology influences the type and complexity of le-
sions the surgeon will encounter in the operating room, which
in turn determines the specific techniques required to achieve
a successful repair. Taking this a step further, because differ-
ent techniques require different levels of surgical expertise
and experience, etiology has a direct implication on choice
of surgeon to perform the operation in a particular patient.
It is therefore imperative that prior to surgical intervention,
the cardiologist and cardiac surgeon make an effort to differ-
entiate the etiology of degenerative disease, as well as the
burden of specific segmental prolapse and lesions, in order
to maximize the likelihood of repair.
Operative Strategy
The etiology of degenerative mitral valve disease has an im-
pact on the complexity and number of repair techniques re-
quired to achieve a successful valve repair, mainly because
of the difference in burden of lesions encountered.8 In fibroe-
lastic deficiency, there is most commonly a single lesion
(chordal rupture) resulting in a single segment prolapse (Fig-
ure 1a), usually the P2 segment of the posterior leaflet. Since
the non-prolapsing segments are usually void of excess leaf-
let tissue, a repair can typically be undertaken by simple re-
section (quadrangular or triangular) of the unsupported
leaflet segment (as in Figure 1b). Alternatively, transfer of
secondary chordae or application of artificial chords can be
used to correct a marginal prolapse without leaflet resection.
As all these techniques are relatively straightforward, it is not
surprising that current repair rates for simple cases of fibroe-
lastic deficiency approach 100% in most tertiary mitral surgi-
cal centers. Furthermore, with simplified approaches such as
limited triangular resections,11 most posterior leaflet prolapse
due to fibroelastic deficiency should be repairable by experi-
enced general cardiac surgeons.
In contradistinction, Barlow’s disease often presents sev-
eral lesions coexisting in multiple segments of the same
valve, which may include chordal elongation, chordal rup-
ture, chordal fusion and fibrosis, excess leaflet tissue, post-
eror leaflet displacement, annular or papillary muscle
calcification, and annular dilatation. The surgical repair ap-
proach should address all lesions present whenever possible.
This often requires advanced repair techniques such as exten-The Journal of Thorsive leaflet resection, leaflet detachment from the annulus,
sliding-plasty to lower the height of remaining posterior leaf-
let segments, multiple chordal transfers or multiple artificial
chordae, and large annuloplasty rings (Figure 1d). Particular
attention must be paid to the amount of residual leaflet tissue
and the annular dimensions after annuloplasty to avoid the
occurrence of systolic anterior motion. A repair of this nature
(as in Figure 1d) predictably requires more skill and exper-
tise than a repair for simple chordal rupture in fibroelastic de-
ficiency (as in Figure 1b). Although we have found it
possible to also achieve repair rate approaching 100% for
Barlow’s valve disease,10 most series suggest a lower repair
rate for Barlow’s compared to fibroelastic disease. This is
evident even in expert series, such as in Flameng et al’s re-
cent series, where their contemporary repair rate for a Barlow
valve was 85% compared to 100% for fibroelastic
deficiency.1
Who Should Perform the Surgery?
There is a general consensus in guidelines that mitral valve
repair is the preferred treatment of degenerative valve dis-
ease, and that in comparison to mitral valve replacement pro-
cedures, it is associated with improved survival in most
patient cohorts.12 Although mitral valve repair rates have
been gradually rising over the past decade, uptake in some
centers remains surprisingly low, especially considering
that the majority of techniques used in valve reconstruction
have been well established since the 1980’s.13 Clearly the is-
sues behind the underutilization of mitral valve repair are
multi-factorial and the path to making it a routine procedure
that is widely available has proven elusive. Specifically, is-
sues including volume and experience as well as referral pat-
terns deserve close scrutiny. Compared to coronary artery
bypass operations and valve replacement procedures, most
cardiac centers do relatively few mitral valve repair proce-
dures for degenerative disease; low volume centers have
lower repair rates.14 In a recent examination of the mitral
valve sub-group in the Euro Heart Survey on Valvular Heart
Disease,15 it was noted that a lack of available expertise (and
not the complexity of the lesions) was given as the reason for
over a third of valve replacement procedures. In an attempt to
address this issue, a multi-disciplinary team in the United
Kingdom suggested one way of increasing mitral valve repair
rates was to establish ‘‘best practice standards’’ that would re-
sult in directed referral to increase volume and experience,
and require mitral valve repair surgeons to perform a mini-
mum of 25 repairs a year.16 Furthermore, it was proposed
that mitral surgeons undergo regular audit, and make not
only their repair rates, but also their incidence of residual
and recurrent mitral regurgitation publicly available. The au-
thors went on to suggest that patients with bileaflet prolapse
or Barlow’s disease should be referred to ‘‘super sub-special-
ists’’ although criteria for such were not defined.16 The logicacic and Cardiovascular Surgery c Volume 136, Number 3 553
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recent article by Flameng et al.1 Although there was an in-
crease in the overall repair rate with accumulating experience
over time, their rate of repair for Barlow’s disease was always
lower than that for fibroelastic deficiency, reinforcing the
complexity of repair in this subgroup.
We believe the next logical step is to recommend inter-
hospital or inter-surgeon comparison of the process and out-
comes of degenerative mitral valve repair including repair
rate, residual or recurrent mitral regurgitation, and reopera-
tion for failed valve repair in clearly defined etiologic
sub-groups. Taking into consideration that the patient with
Barlow’s disease is generally younger, he or she has the
most to benefit from valve repair, as opposed to replacement,
so given the anticipated complexity of repair in such patients,
a documented repair rate for this condition should be made
available to these patients as part of the informed consent.
Many experienced cardiac surgeons will have a success
rate in excess of 90% for simple P2 prolapse in the setting
of fibroelastic deficiency, but have a low repair rate for Bar-
low’s valves. Requiring surgeons undertaking mitral repair
surgery to perform at least 25 repairs a year,16 does not go
far enough, as etiology and lesion complexity, rather than
volume alone, is critical to understanding the true repair rates
a specific patient can expect from a given surgeon. For exam-
ple, a surgeon who does 30 mitral valve procedures a year
with an 83% repair rate, could have repaired 10 of 10 ische-
mic mitral valves cases (100%), 14 of 15 cases (93%) of fi-
broelastic deficiency with posterior leaflet prolapse, but
only 1 of 5 cases (20%) with Barlow’s disease, so quoting
the 83% repair rate to a patient with Barlow’s would be mis-
leading. Ideally therefore, differentiation between Barlow’s
and fibroelastic deficiency, as well as simple vs. complex le-
sions, should take place pre-operatively as a surgical team
should only undertake an operation on a patient who requires
a complex repair if it is well versed in the advanced tech-
niques needed to achieve a complex valve reconstruction.
The referring cardiologist should make a specific attempt to
define the likelihood of repairability of the valve based on
the etiology and complexity of lesions seen on echocardiog-
raphy and the surgical experience in their own center.17 Pa-
tients with a projected low likelihood of repair in their local
center, especially the young Barlow patient, should be re-
ferred to a regional reference center with an more established
track record in complex repair. Likewise, the surgeon should
give an honest assessment of the likelihood of a achieving
a successful repair based on their own experience with the eti-
ologic group and specific lesions in the patient being consid-
ered for surgery. If the honest expectation, based on volume
and expertise, is that there is a good chance a valve replace-
ment will be required for the degenerative disease encoun-
tered, the surgeon should be open about this with the
patient, and consider offering a second opinion with a more
experienced valve repair surgeon.554 The Journal of Thoracic and Cardiovascular Surgery c SepImplications for Future Outcome Studies
Data from Flameng and associates1 suggest that when ad-
justment has been made for ‘surgical risk factors’, patients
have a similar linearized rate of recurrent regurgitation after
mitral valve repair regardless of whether the original disease
was Barlow’s (2.9% per year) or fibroelastic deficiency
(2.2% per year). Because of aforementioned limitations,
especially with the classification approach and surgical
methods employed, we cannot be certain that this observa-
tion is valid. The long term freedom from moderate or
severe regurgitation was certainly disappointing in Fla-
meng’s series (35% having moderate or severe regurgitation
at 10 years1) and is worse than reported in a contemporary
series from David’s group (19% at 10 years18). Use of di-
verse surgical techniques and an inevitable learning curve
in the early part of any series (evident in Flameng et al’s
study by an initial low repair rate for Barlow’s disease
which increased over the study period1), could contribute
to a high rate of recurrent regurgitation as patients operated
in the early part of a series are those that have the long-term
follow-up.7 Inferior surgical techniques may contribute to
inferior long-term outcome. For example, chordal shorten-
ing, employed in 15% and the non-use of an annuloplasty
ring in 5% of Barlow repairs in Flameng et al’s series,1
are predictors of recurrent mitral regurgitation.1,6 In reality,
we still do not know if the longevity of a Barlow repair dif-
fers from that of repair for fibroelastic deficiency. There are
data suggesting that bileaflet and anterior leaflet repairs are
less durable than posterior leaflet repairs2,5 – as bileaflet
prolapse is more commonly associated with Barlow’s, one
would, therefore, expect that more Barlow repairs would
fail in the long term than repairs for fibroelastic deficiency.
However, we do not know whether there is a difference in
durability of repair between similar dysfunctions of differ-
ent etiology (e.g. posterior leaflet prolapse in Barlow’s ver-
sus posterior leaflet prolapse in fibroelastic deficiency). We
suspect that the two diseases are indeed different: even after
successful reconstruction, there remain differences in the re-
constructed valve morphology, and in techniques utilized to
achieve the repair, (see Figure 1b and 1d) such that the po-
tential for recurrent mitral regurgitation due to technical
failure or disease progression would likely differ (with
greater likelihood of recurrence in Barlow’s disease). Future
studies will test this hypothesis. Similarly, when assessing
the results of a particular technique, it is important to
know what disease the technique has been applied for: the
long term results of a single artificial chord to repair P2 pro-
lapse in the setting of fibroelastic deficiency may be differ-
ent from that of multiple artificial chords used to support
extensive posterior leaflet prolapse in Barlow’s disease.
These questions can only be answered by accurate surgical
differentiation of valve lesions and etiology at the time of
surgery, near-complete long term follow-up and appropriatetember 2008
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by etiology will bear increasing relevance in coming years
because of the increasing number of patients undergoing
surgery for asymptomatic disease, the majority of which
will likely have Barlow’s disease. In order to counsel pa-
tients, we should be aware of the likelihood of long-term re-
currence based on the etiology and lesions, and also the
techniques employed in the reconstructive procedure.
Learning from Unplanned Mitral Valve Replacement
Prospective documentation of etiology and lesions is also im-
portant for those valves which are replaced for degenerative
disease. For example, although the replacement rate for de-
generative disease in Flameng et al’s recent series was
23%,1 the authors did not provide any information on the re-
placement group, preventing the reader from learning from
the group that had failed or un-attempted repairs. We would
recommend that in future studies the specific reasons for
valve replacement for degenerative disease should be scruti-
nized. Additionally, we suggest that surgeons record in the
operative report for all mitral valve replacements, what spe-
cific lesion(s) made the valve ‘‘irrepairable’’. This may one
day help establish a ‘‘repairabilty index or score’’ which
may help in preoperative stratification. Requiring surgeons
to document precisely why they replace a valve may also in-
crease repair rates as it would force the surgeon to adopt a le-
sion and etiology based approach, and additionally provide
an important benchmark of quality assessment (by enabling
monitoring of the appropriateness of valve replacement).
This is particularly relevant in the asymptomatic patient
with severe mitral regurgitation with degenerative valve dis-
ease, where guidelines suggest at least a 90% possibility of
repair should exist before subjecting an asymptomatic patient
to surgery.12
Where to go Next?
We see systematic application of etiologic differentiation as
the next chapter in outcomes research in degenerative mi-
tral valve repair. It should no longer be sufficient to de-
scribe the outcomes of mitral valve repair in terms of
patient survival or freedom from reoperation for a mixed
cohort of patients with ‘‘degenerative disease’’, or ‘‘mitral
valve prolapse’’, or ‘‘floppy valves’’ as we have done in
the past. In this era, we should make an attempt to separate
Barlow patients from those with fibroelastic deficiency (rec-
ognizing some patients will not be classifiable) and provide
readers with clear echocardiographic and surgically derived
data on the lesions present and techniques employed to
treat them. At some point it will be necessary for our Soci-
eties to convene an expert panel to agree on a uniform clas-
sification for mitral valve lesions and etiology. With this we
can ultimately move to the next level of differentiating de-
generative mitral valve disease: offering our patients coun-The Journal of Thorseling, therapy and informed data on outcomes of surgical
intervention based on the specific etiology, lesions and dys-
functions a patient has, rather than solely on leaflet involve-
ment or mixed etiologic experiences. Without question,
adoption of etiologic differentiation of degenerative disease
by cardiologists and cardiac surgeons will lead to more
valve repairs, better quality repairs, and better quality valve
outcomes research. We strongly encourage the increased
use of etiologic and lesion based differentiation in surgical
practice and reporting, as we believe this will herald a new
and exciting era of higher quality mitral valve repair and
outcomes analysis.
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